USP28 enables oncogenic transformation of respiratory cells and its inhibition potentiates molecular therapy targeting mutant EGFR, BRAF and PI3K.
C. Prieto-Garcia, O. Hartmann, M. Reissland, F. Braun, S. Bozkurt, C. T. Fuss, C. Schuelein-Voelk, A. Buchberger, M. A. Calzado, M. T. Rosenfeldt, I. Dikic, C. Muench, M. E. Diefenbacher
This study shows USP28 promotes lung cancer by stabilizing oncogenes and its inhibition enhances therapy for EGFR, BRAF, and PI3K mutant tumors.
bioRxiv · Sep 6, 2021Cancer Biology